Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 85,700 shares, an increase of 724.0% from the February 13th total of 10,400 shares. Currently, 5.5% of the shares of the company are sold short. Based on an average daily volume of 2,040,000 shares, the short-interest ratio is presently 0.0 days.

Salarius Pharmaceuticals Price Performance

NASDAQ SLRX opened at $0.96 on Friday. The company has a market capitalization of $1.52 million, a PE ratio of -0.12 and a beta of 0.59. The company has a fifty day moving average of $1.81 and a 200 day moving average of $1.64. Salarius Pharmaceuticals has a 1 year low of $0.90 and a 1 year high of $7.20.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.